Structural studies on a non-toxic homologue of type II RIPs from bitter gourd: Molecular basis of non-toxicity, conformational selection and glycan structure

2015 ◽  
Vol 40 (5) ◽  
pp. 929-941 ◽  
Author(s):  
Thyageshwar Chandran ◽  
Alok Sharma ◽  
M Vijayan
1998 ◽  
Vol 80 (09) ◽  
pp. 376-381 ◽  
Author(s):  
W. Lissens ◽  
S. Seneca ◽  
P. Capel ◽  
B. Chatelain ◽  
P. Meeus ◽  
...  

SummaryThe molecular basis of hereditary antithrombin (AT) deficiency has been investigated in ten Belgian and three Dutch unrelated kindreds. Eleven of these families had a quantitative or type I AT deficiency, with a history of major venous thromboembolic events in different affected members. In the other two families a qualitative or type II AT deficiency was occasionally diagnosed.DNA studies of the AT gene were performed, using polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) analysis, followed by direct sequencing of the seven exons and intronexon junction regions. Six novel point mutations were identified: four missense, one nonsense mutation and a single nucleotide deletion near the reactive site, causing a frameshift with premature translation termination. In two kindreds the underlying genetic defect was caused by a whole gene deletion, known as a rare cause of AT deficiency. In these cases, Southern blot and polymorphism analysis of different parts of the AT gene proved useful for diagnosis. In another kindred a partial gene deletion spanning 698 basepairs could precisely be determined to a part of intron 3B and exon 4. In two type I and in both type II AT deficient families a previously reported mutation was identified. In all cases, the affected individuals were heterozygous for the genetic defect.


PEDIATRICS ◽  
2003 ◽  
Vol 112 (Supplement_4) ◽  
pp. 1557-1565
Author(s):  
Heidi Erlandsen ◽  
Marianne G. Patch ◽  
Alejandra Gamez ◽  
Mary Straub ◽  
Raymond C. Stevens

Mutations in the gene encoding for phenylalanine hydroxylase (PAH) result in phenylketonuria (PKU) or hyperphenylalaninemia (HPA). Several 3-dimensional structures of truncated forms of PAH have been determined in our laboratory and by others, using x-ray crystallographic techniques. These structures have allowed for a detailed mapping of the >250 missense mutations known to cause PKU or HPA found throughout the 3 domains of PAH. This structural information has helped formulate rules that might aid in predicting the likely effects of unclassified or newly discovered PAH mutations. Also, with the aid of recent crystal structure determinations of co-factor and substrate analogs bound at the PAH active site, the recently discovered tetrahydrobiopterin-responsive PKU/HPA genotypes can be mapped onto the PAH structure, providing a molecular basis for this tetrahydrobiopterin response.


Bone ◽  
1985 ◽  
Vol 6 (1) ◽  
pp. 55-56
Author(s):  
L.J. Fraher ◽  
G.N. Hendy ◽  
H. Jani ◽  
L. Nicholson ◽  
F.R.J. Hinde ◽  
...  

2010 ◽  
Vol 25 (9) ◽  
pp. 560-564 ◽  
Author(s):  
K J Carss ◽  
M Stowasser ◽  
R D Gordon ◽  
K M O'Shaughnessy

1997 ◽  
Vol 15 (12) ◽  
pp. 1529-1530
Author(s):  
A Li ◽  
R Tedde ◽  
M Palermo ◽  
C H.L. Shackleton ◽  
P M. Stewart

2002 ◽  
Vol 161 (6) ◽  
pp. 2027-2034 ◽  
Author(s):  
Guido A. Hegasy ◽  
Tamara Manuelian ◽  
Kolbjorn Hogasen ◽  
Johan H. Jansen ◽  
Peter F. Zipfel

2005 ◽  
Vol 7 (3) ◽  
pp. 1-17 ◽  
Author(s):  
Samantha Holmes ◽  
Manuel A. Friese ◽  
Christian Siebold ◽  
E. Yvonne Jones ◽  
John Bell ◽  
...  

Multiple sclerosis (MS) is an autoimmune disease with an important genetic component. The strongest genetic association is with the major histocompatibility complex (MHC) region. Several MHC alleles predispose to the disease, the most prominent of which are certain alleles in the HLA-DR2 haplotype. Functional and structural studies have helped to explain the molecular basis of these associations. Although there is currently no curative treatment for MS, an increased understanding of the disease has aided the design of immunotherapies that act on the immune system more specifically than the longstanding drugs. Many of these therapies work at the antigen-specific level, disrupting the interaction between T-cell receptors and MHC molecules that leads to disease.


1999 ◽  
Vol 104 (1) ◽  
pp. 94-98 ◽  
Author(s):  
M. L. Huie ◽  
A. L. Shanske ◽  
J. S. Kasper ◽  
R. W. Marion ◽  
R. Hirschhorn

Sign in / Sign up

Export Citation Format

Share Document